

# Helen Tremlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/384850/publications.pdf>

Version: 2024-02-01

246  
papers

11,585  
citations

30070

54  
h-index

36028

97  
g-index

249  
all docs

249  
docs citations

249  
times ranked

10383  
citing authors

#	ARTICLE	IF	CITATIONS
1	Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada. <i>Multiple Sclerosis Journal</i> , 2022, 28, 309-322.	3.0	4
2	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. <i>Neurology</i> , 2022, 98, .	1.1	15
3	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1819-1824.	3.0	2
4	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1825-1828.	3.0	1
5	Disease-modifying drugs for multiple sclerosis and subsequent health service use. <i>Multiple Sclerosis Journal</i> , 2022, 28, 583-596.	3.0	6
6	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103829.	2.0	8
7	Multiple sclerosis incidence: A systematic review of change over time by geographical region. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103932.	2.0	21
8	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	11
9	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	10.1	23
10	Accurate classification of secondary progression in multiple sclerosis using a decision tree. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1240-1249.	3.0	14
11	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 239-249.	3.0	5
12	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , 2021, 27, 290-302.	3.0	33
13	The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. <i>Multiple Sclerosis Journal</i> , 2021, 27, 6-12.	3.0	50
14	The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	2
15	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 131-140.	2.8	11
16	Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort. <i>American Journal of Epidemiology</i> , 2021, 190, 908-917.	3.4	6
17	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0
18	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 481-487.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e043930.	1.9	9
20	The multiple sclerosis prodrome. <i>Nature Reviews Neurology</i> , 2021, 17, 515-521.	10.1	52
21	Coexistence of Multiple Sclerosis and Alzheimer Disease Pathology: A Case Series. <i>Journal of Neurology Research</i> , 2021, 11, 60-67.	0.5	2
22	Gut microbiome is associated with multiple sclerosis activity in children. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1867-1883.	3.7	21
23	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients – No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1824-1826.	3.0	5
24	A multiple sclerosis disease progression measure based on cumulative disability. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852098863.	3.0	3
25	High BMI in Youths as a Modifiable Risk Factor for Multiple Sclerosis. <i>Neurology</i> , 2021, 97, 1057-1058.	1.1	1
26	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	4.8	4
27	The Multiple Sclerosis Prodrome: Evidence to Action. <i>Frontiers in Neurology</i> , 2021, 12, 761408.	2.4	14
28	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2252-2269.	3.7	34
29	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1560-1568.	3.0	8
30	The multiple sclerosis gut microbiota: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101427.	2.0	102
31	Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1510-1518.	3.0	18
32	Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis. <i>Drugs and Aging</i> , 2020, 37, 225-235.	2.7	12
33	Causes that Contribute to the Excess Mortality Risk in Multiple Sclerosis: A Population-Based Study. <i>Neuroepidemiology</i> , 2020, 54, 131-139.	2.3	22
34	Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102566.	2.0	8
35	Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1069-1094.	2.4	26
36	Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of childbearing age. <i>European Journal of Neurology</i> , 2020, 27, 2625-2629.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	17
38	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	3.0	21
39	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	3.0	39
40	Alemtuzumab and prescription medication use in the MS population. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102086.	2.0	1
41	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 799-819.	2.8	26
42	Multiple cause of death analysis in multiple sclerosis. <i>Neurology</i> , 2020, 94, e820-e829.	1.1	25
43	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , 2020, 54, 140-147.	2.3	9
44	Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States. <i>Neuroepidemiology</i> , 2020, 54, 123-130.	2.3	4
45	The future of microbiome research in neuroinflammatory disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 102098.	2.0	0
46	Predicting risk of secondary progression in multiple sclerosis: A nomogram. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1102-1112.	3.0	53
47	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1092-1101.	3.0	66
48	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 42-49.	2.0	5
49	Reply to letter to the editor. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 165.	2.0	0
50	Prodrome in relapsing&#x2013;remitting and primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1032-1036.	3.3	23
51	Adjusting for differential misclassification in matched case&#x2013;control studies utilizing health administrative data. <i>Statistics in Medicine</i> , 2019, 38, 3669-3681.	1.6	3
52	Multiple sclerosis: effect of beta interferon treatment on survival. <i>Brain</i> , 2019, 142, 1324-1333.	7.6	34
53	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. <i>Neurology</i> , 2019, 92, e1624-e1633.	1.1	23
54	Socioeconomic status and disability progression in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1497-e1506.	1.1	45

#	ARTICLE	IF	CITATIONS
55	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.1	765
56	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.1	69
57	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.1	40
58	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 138-144.	2.0	4
59	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 364-369.	2.0	20
60	Animal exposure over the life-course and risk of multiple sclerosis: A case-control study within two cohorts of US women. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 327-332.	2.0	5
61	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 232-238.	2.0	32
62	Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 251-260.	1.9	36
63	The Microbiome in Multiple Sclerosis. , 2019, , 121-146.		0
64	The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 30-34.	2.0	8
65	Sun exposure over the life course and associations with multiple sclerosis. <i>Neurology</i> , 2018, 90, e1191-e1199.	1.1	44
66	Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011â€“2016). <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 169-177.	2.0	43
67	Can falling infection rates in one country explain rising incidence of autoimmune and allergic diseases in other countries? Caution when (over) interpreting ecological data from disparate areas. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, A3-A5.	2.0	1
68	Gut microbiome and pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 64-68.	3.0	23
69	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e419-e427.	1.1	67
70	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1050-1056.	1.9	80
71	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1316-e1323.	1.1	136
72	Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1709-1722.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
74	An "epidemic" of multiple sclerosis and falling infection rates? Reflecting on comparisons made and the rising multiple sclerosis incidence in Bach's 2002 <i>New England Journal of Medicine</i> figure. <i>European Journal of Neurology</i> , 2018, 25, 196-199.	3.3	1
75	The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings. <i>Neurotherapeutics</i> , 2018, 15, 102-108.	4.4	14
76	Drug exposure and the risk of multiple sclerosis: A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 133-139.	1.9	8
77	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 76-84.	1.0	35
78	WED 167 Socioeconomic status and progression of disability in ms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A21.1-A21.	1.9	0
79	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1211-1221.	3.7	55
80	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018, 51, 1-10.	2.3	18
81	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 57-60.	2.0	8
82	Common variation near IRF6 is associated with IFN- $\gamma$ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	21.4	32
83	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 232-240.	2.0	18
84	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 258-264.	2.0	6
85	A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?. <i>Frontiers in Microbiology</i> , 2018, 9, 3249.	3.5	80
86	Disability progression in aggressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 456-463.	3.0	14
87	Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. <i>NeuroToxicology</i> , 2017, 61, 189-212.	3.0	83
88	The gut microbiome in human neurological disease: A review. <i>Annals of Neurology</i> , 2017, 81, 369-382.	5.3	388
89	Increased incidence and prevalence of psoriasis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 81-86.	2.0	28
90	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1506-1516.	3.0	76

#	ARTICLE	IF	CITATIONS
91	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 445-451.	10.2	105
92	Determinants of neurological disease: Synthesis of systematic reviews. <i>NeuroToxicology</i> , 2017, 61, 266-289.	3.0	22
93	Evaluating the safety of $\hat{I}^2$ -interferons in MS. <i>Neurology</i> , 2017, 88, 2310-2320.	1.1	45
94	Age Related Multiple Sclerosis Severity Score: Disability ranked by age. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1938-1946.	3.0	107
95	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a caseâ€control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , 2017, 7, e016276.	1.9	2
96	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 702-711.	1.9	27
97	Primary and secondary progressive MS have a similar age at onset of progression â€NO. <i>Multiple Sclerosis Journal</i> , 2017, 23, 640-642.	3.0	7
98	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e018612.	1.9	4
99	Concussion may not cause multiple sclerosis. <i>Annals of Neurology</i> , 2017, 82, 651-652.	5.3	2
100	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017, 48, 124-130.	2.3	6
101	Bayesian analysis of pairâ€matched caseâ€control studies subject to outcome misclassification. <i>Statistics in Medicine</i> , 2017, 36, 4196-4213.	1.6	4
102	Author response: Evaluating the safety of $\hat{I}^2$ -interferons in MS: A series of nested case-control studies. <i>Neurology</i> , 2017, 89, 2022-2023.	1.1	0
103	Comorbidity increases the risk of relapse in multiple sclerosis. <i>Neurology</i> , 2017, 89, 2455-2461.	1.1	77
104	On the application of statistical learning approaches to construct inverse probability weights in marginal structural Cox models: Hedging against weight-model misspecification. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2017, 46, 7668-7697.	1.2	8
105	Genetic variation associated with the occurrence and progression of neurological disorders. <i>NeuroToxicology</i> , 2017, 61, 243-264.	3.0	18
106	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 588-596.	3.0	44
107	The multiple sclerosis microbiome?. <i>Annals of Translational Medicine</i> , 2017, 5, 53-53.	1.7	18
108	Contents Vol. 48, 2017. <i>Neuroepidemiology</i> , 2017, 48, I-IV.	2.3	0

#	ARTICLE	IF	CITATIONS
109	Reproductive Issues in Multiple Sclerosis: Parental MS and Child Outcomes (The Research Perspective). , 2017, , 63-72.		0
110	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. European Journal of Neurology, 2016, 23, 1093-1100.	3.3	29
111	Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression. Pharmacoepidemiology and Drug Safety, 2016, 25, 1150-1159.	1.9	4
112	Gut microbiota in early pediatric multiple sclerosis: a case-control study. European Journal of Neurology, 2016, 23, 1308-1321.	3.3	260
113	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2016, 8, 78-85.	2.0	53
114	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. Multiple Sclerosis and Related Disorders, 2016, 8, 86-92.	2.0	14
115	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 120-128.	1.6	42
116	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain and Behavior, 2016, 6, e00493.	2.2	24
117	Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis. Paediatric and Perinatal Epidemiology, 2016, 30, 356-366.	1.7	15
118	Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies. American Journal of Epidemiology, 2016, 184, 325-335.	3.4	68
119	Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neurology, 2016, 16, 182.	1.8	91
120	THE AUTHORS REPLY. American Journal of Epidemiology, 2016, 184, 857-858.	3.4	1
121	Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. Multiple Sclerosis Journal, 2016, 22, 1452-1462.	3.0	24
122	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.6	137
123	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 2016, 86, 1287-1295.	1.1	79
124	Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. Multiple Sclerosis Journal, 2016, 22, 1830-1840.	3.0	16
125	Health-related quality of life in multiple sclerosis. Neurology, 2016, 86, 1417-1424.	1.1	156
126	Sex differences in comorbidity at diagnosis of multiple sclerosis. Neurology, 2016, 86, 1279-1286.	1.1	86



#	ARTICLE	IF	CITATIONS
127	Multiple sclerosis in men: management considerations. <i>Journal of Neurology</i> , 2016, 263, 1263-1273.	3.6	30
128	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 685-693.	3.0	27
129	Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F114-F120.	2.8	42
130	Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. <i>Health Technology Assessment</i> , 2016, 20, 1-48.	2.8	20
131	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 96-104.	1.0	38
132	Management of Multiple Sclerosis During Pregnancy and the Reproductive Years. <i>Obstetric Anesthesia Digest</i> , 2015, 35, 186-187.	0.1	3
133	Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	40
134	Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	76
135	A longitudinal model for disease progression was developed and applied to multiple sclerosis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1355-1365.	5.0	20
136	Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1172-1183.	3.0	15
137	The systematic search for risk factors in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 237-238.	10.2	7
138	Serum proteomics in multiple sclerosis disease progression. <i>Journal of Proteomics</i> , 2015, 118, 2-11.	2.4	27
139	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). <i>Journal of Neurology</i> , 2015, 262, 2352-2363.	3.6	100
140	Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. <i>Lancet Neurology</i> , The, 2015, 14, 497-505.	10.2	91
141	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 470-476.	2.0	40
142	Differences in the burden of psychiatric comorbidity in MS vs the general population. <i>Neurology</i> , 2015, 85, 1972-1979.	1.1	106
143	Beta-interferon exposure and onset of secondary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 990-1000.	3.3	34
144	Health-related quality of life in patients with longstanding "benign" multiple sclerosis™. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 31-38.	2.0	9

#	ARTICLE	IF	CITATIONS
145	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1305-1317.	2.4	8
146	Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. <i>Neurology</i> , 2014, 83, 1022-1024.	1.1	953
147	THE UK MS RISK-SHARING SCHEME: RESULTS FOR YEARS 4 AND 6. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.24-e4.	1.9	1
148	UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. <i>BMJ Open</i> , 2014, 4, e004073.	1.9	66
149	Birth outcomes of pregnancies fathered by men with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1260-1264.	3.0	19
150	Children of chronically ill parents: the silence of research. <i>Child: Care, Health and Development</i> , 2014, 40, 753-754.	1.7	2
151	Management of Multiple Sclerosis During Pregnancy and the Reproductive Years. <i>Obstetrics and Gynecology</i> , 2014, 124, 1157-1168.	2.4	109
152	Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. <i>European Journal of Neurology</i> , 2014, 21, 835-844.	3.3	11
153	A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis. <i>CNS Drugs</i> , 2014, 28, 89-94.	5.9	29
154	Assessment of cancer risk with $\hat{I}^2$ -interferon treatment for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1096-1102.	1.9	29
155	Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs. <i>CNS Drugs</i> , 2014, 28, 475-82.	5.9	9
156	Children and adolescents adjustment to parental multiple sclerosis: a systematic review. <i>BMC Neurology</i> , 2014, 14, 107.	1.8	25
157	Marginal Structural Cox Models for Estimating the Association Between $\hat{I}^2$ -Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. <i>American Journal of Epidemiology</i> , 2014, 180, 160-171.	3.4	61
158	Association between beta-interferon exposure and hospital events in multiple sclerosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1213-1222.	1.9	9
159	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-153.	1.3	17
160	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-53.	1.3	8
161	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. <i>BMC Neurology</i> , 2013, 13, 16.	1.8	122
162	Obstetrical epidural and spinal anesthesia in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2620-2628.	3.6	29

#	ARTICLE	IF	CITATIONS
163	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 183-192.	2.0	7
164	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 355-361.	2.0	34
165	Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 251-261.	2.8	29
166	Birth outcomes of pregnancies fathered by men with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 333, e381.	0.6	0
167	A proposed methodology to estimate the cumulative life-time UVB exposure using geographic information systems: An application to multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 29-35.	2.0	6
168	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 57-59.	2.0	12
169	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. <i>Neuroepidemiology</i> , 2013, 40, 85-92.	2.3	62
170	Birth hospitalization in mothers with multiple sclerosis and their newborns. <i>Neurology</i> , 2013, 80, 447-452.	1.1	26
171	IMPROVING THE MODEL FOR THE UK MS DISEASE MODIFYING TREATMENT RISK SHARING SCHEME ANALYSIS: A NEW NATURAL HISTORY DATASET. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.97-e2.	1.9	0
172	Characterising aggressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1192-1198.	1.9	71
173	Retinal nerve fiber layer thickness in benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1275-1281.	3.0	23
174	Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. <i>Multiple Sclerosis Journal</i> , 2013, 19, 577-584.	3.0	41
175	Interferon Beta and Long-term Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 651.	9.0	4
176	Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. <i>Neurology</i> , 2013, 80, 1068-1069.	1.1	4
177	Labor induction and augmentation in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1182-1189.	3.0	9
178	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 824-831.	0.5	53
179	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 824-31.	0.5	20
180	Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions - No. <i>Multiple Sclerosis Journal</i> , 2012, 18, 138-139.	3.0	1

#	ARTICLE	IF	CITATIONS
181	Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. <i>Multiple Sclerosis Journal</i> , 2012, 18, 460-467.	3.0	51
182	Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). <i>Multiple Sclerosis Journal</i> , 2012, 18, 442-450.	3.0	50
183	Treatment With Interferon Beta for Multiple Sclerosis-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1627.	7.4	4
184	Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1239-1243.	3.0	15
185	Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 247-56.	7.4	234
186	Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 61-66.	1.9	129
187	Natural, innate improvements in multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1412-1421.	3.0	23
188	The risks for falls and fractures in multiple sclerosis. <i>Neurology</i> , 2012, 78, 1902-1903.	1.1	3
189	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1310-1319.	3.0	109
190	The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data. <i>Neuroepidemiology</i> , 2012, 39, 135-142.	2.3	35
191	Cancer risk in multiple sclerosis: findings from British Columbia, Canada. <i>Brain</i> , 2012, 135, 2973-2979.	7.6	82
192	Disease-modifying drugs for multiple sclerosis in pregnancy. <i>Neurology</i> , 2012, 79, 1130-1135.	1.1	150
193	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 162-167.	2.0	24
194	Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study. <i>Clinical Therapeutics</i> , 2012, 34, 341-350.	2.5	36
195	Hospital admissions and MS: temporal trends and patient characteristics. <i>American Journal of Managed Care</i> , 2012, 18, 735-42.	1.1	24
196	The psychosocial and cognitive impact of longstanding "benign" multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1375-1383.	3.0	24
197	Symptomatic liver injury (hepatotoxicity) associated with administration of complementary and alternative products (Ayurveda-AP-Mag Capsules®) in a beta-interferon-treated multiple sclerosis patient. <i>European Journal of Neurology</i> , 2011, 18, e78-e79.	3.3	7
198	Neonatal and delivery outcomes in women with multiple sclerosis. <i>Annals of Neurology</i> , 2011, 70, 41-50.	5.3	94

#	ARTICLE	IF	CITATIONS
199	High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 361-367.	3.0	19
200	Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 193-203.	5.3	388
201	The effect of smoking on the symptoms and progression of multiple sclerosis: a review. <i>Journal of Inflammation Research</i> , 2010, 3, 115.	3.5	15
202	The natural history of secondary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1039-1043.	1.9	191
203	Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. <i>Neurology</i> , 2010, 74, 1822-1826.	1.1	82
204	Disease onset in familial and sporadic primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 694-700.	3.0	14
205	New perspectives in the natural history of multiple sclerosis. <i>Neurology</i> , 2010, 74, 2004-2015.	1.1	226
206	Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. <i>Journal of the Neurological Sciences</i> , 2010, 292, 57-62.	0.6	37
207	Multiple sclerosis and pregnancy. <i>Neurology</i> , 2009, 73, 1820-1822.	1.1	63
208	Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. <i>Multiple Sclerosis Journal</i> , 2009, 15, 521-522.	3.0	7
209	Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. <i>Journal of Neurology</i> , 2009, 256, 374-381.	3.6	69
210	Increasing Levels of Serum Vitamin D are Associated with Lower Rates of Relapse in Multiple Sclerosis. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1520.	1.5	1
211	Interferons and multiple sclerosis: is it plausible that $\beta$ -IFN treatment could influence the risk of cancer among MS patients?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1263-1265.	2.8	8
212	The natural history of primary progressive multiple sclerosis. <i>Neurology</i> , 2009, 73, 1996-2002.	1.1	156
213	Impact of multiple sclerosis relapses on progression diminishes with time. <i>Neurology</i> , 2009, 73, 1616-1623.	1.1	200
214	Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon- $\beta$ . <i>European Journal of Neurology</i> , 2008, 15, e4.	3.3	7
215	Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 565-576.	1.9	73
216	Interferon- $\beta$ treatment and the natural history of relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 125-126.	5.3	6

#	ARTICLE	IF	CITATIONS
217	Relapses in multiple sclerosis are age- and time-dependent. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1368-1374.	1.9	194
218	Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis. <i>Neuroepidemiology</i> , 2008, 31, 271-279.	2.3	142
219	Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. <i>Multiple Sclerosis Journal</i> , 2008, 14, 94-105.	3.0	21
220	Natural history of secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 314-324.	3.0	187
221	Author Index Vol. 31, 2008. <i>Neuroepidemiology</i> , 2008, 31, 285-285.	2.3	0
222	Timing of birth and disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 793-798.	3.0	14
223	Defining the natural history of MS: the need for complete data and rigorous definitions. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1142-1143.	3.0	2
224	Subject Index Vol. 31, 2008. <i>Neuroepidemiology</i> , 2008, 31, 286-286.	2.3	0
225	Contents Vol. 31, 2008. <i>Neuroepidemiology</i> , 2008, 31, I-IV.	2.3	0
226	Primary and Nonprimary Fatigue in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2008, 10, 14-20.	1.0	11
227	Longitudinal follow-up of "benign" multiple sclerosis at 20 years. <i>Neurology</i> , 2007, 68, 496-500.	1.1	132
228	What went wrong in the natalizumab trials Comment?. <i>Lancet, The</i> , 2006, 367, 1484-1485.	13.7	2
229	Is late-onset multiple sclerosis associated with a worse outcome?. <i>Neurology</i> , 2006, 67, 954-959.	1.1	95
230	Does the Season or Month of Birth Influence Disease Progression in Multiple Sclerosis?. <i>Neuroepidemiology</i> , 2006, 26, 195-198.	2.3	18
231	Contents Vol. 26, 2006. <i>Neuroepidemiology</i> , 2006, 26, 243-244.	2.3	1
232	Subject Index Vol. 26, 2006. <i>Neuroepidemiology</i> , 2006, 26, 242-242.	2.3	0
233	Author Index Vol. 26, 2006. <i>Neuroepidemiology</i> , 2006, 26, 240-241.	2.3	0
234	Liver test abnormalities in multiple sclerosis: Findings from placebo-treated patients. <i>Neurology</i> , 2006, 67, 1291-1293.	1.1	13

#	ARTICLE	IF	CITATIONS
235	Disability progression in multiple sclerosis is slower than previously reported. <i>Neurology</i> , 2006, 66, 172-177.	1.1	303
236	The natural history of primary progressive MS in British Columbia, Canada. <i>Neurology</i> , 2005, 65, 1919-1923.	1.1	94
237	Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. <i>Neurology</i> , 2005, 64, 174-175.	1.1	2
238	Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. <i>Multiple Sclerosis Journal</i> , 2004, 10, 298-301.	3.0	23
239	Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1297-1303.	3.6	41
240	Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. <i>Neurology</i> , 2002, 58, 1868-1868.	1.1	2
241	Asthma and multiple sclerosis: an inverse association in a case-control general practice population. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2002, 95, 753-756.	0.5	54
242	Prescribing for multiple sclerosis patients in general practice: a case-control study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 437-444.	1.5	19
243	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 50, 422-422.	5.3	3
244	Nonprescription medicine use in a multiple sclerosis clinic population. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 55-60.	2.4	4
245	General practitioners' prescribing data for multiple sclerosis patients indicates a link with asthma. <i>British Journal of General Practice</i> , 2000, 50, 323-4.	1.4	4
246	The epidemiology of multiple sclerosis. , 0, , 46-55.		0